Ra Pharma files $100M round as Soliris rival clears phase 2 trial

Armed with a phase 2 win for its lead drug zilucoplan in rare disease myasthenia gravis, Ra Pharma has pressed the button on a public funding round that it hopes could raise up to $115 million.